| Perindopril, Indapamide |
20110360 |
Pontea, Film coated tablet, 4 mg/ 1,25 mg, mg, Pack: 30 |
Stada Arzneimittel AG, Германия |
Glenmark Pharmaceutical Ltd – UK; Glenmark Pharmaceutical sro – Czech Republic |
6.2 |
1.24 |
7.44 |
7% |
0.43 |
6.63 |
1.33 |
7.96 |
20% |
1.24 |
7.87 |
1.57 |
9.44 |
|
НСР-6149/29.04.2015. |
14.05.2015 |
14.05.2015 |
Неактивен |
3864 |
| Perindopril, Indapamide |
20110359 |
Pontea, Film coated tablet, 2 mg/ 0,625 mg, mg, Pack: 30 |
Stada Arzneimittel AG, Германия |
STADA Arzneimittel AG, Stadastrasse 2-18, 61118 Bad Vilbel, Германия |
3.64 |
0.73 |
4.37 |
7% |
0.25 |
3.89 |
0.78 |
4.67 |
20% |
0.73 |
4.62 |
0.92 |
5.54 |
промяна на обстоятелства НСР-10049/18.08.2016 |
НСР-2504/24.01.2014 |
14.02.2014 |
02.10.2016 |
Активен |
2479 |
| Perindopril, Indapamide |
20110359 |
Pontea, Film coated tablet, 2 mg/ 0,625 mg, mg, Pack: 30 |
Stada Arzneimittel AG, Германия |
Glenmark Pharmaceutical Ltd – UK; Glenmark Pharmaceutical sro – Czech Rep. |
3.64 |
0.73 |
4.37 |
7% |
0.25 |
3.89 |
0.78 |
4.67 |
20% |
0.73 |
4.62 |
0.92 |
5.54 |
|
НСР-2504/24.01.2014 |
14.02.2014 |
14.02.2014 |
Неактивен |
2479 |
| Perindopril, Indapamide |
20110360 |
Pontea, Film coated tablet, 4 mg/ 1,25 mg, mg, Pack: 30 |
Stada Arzneimittel AG, Германия |
Glenmark Pharmaceutical Ltd – UK; Glenmark Pharmaceutical sro – Czech Rep |
7.53 |
1.51 |
9.04 |
7% |
0.53 |
8.06 |
1.61 |
9.67 |
20% |
1.51 |
9.57 |
1.91 |
11.48 |
|
НСР-2505/24.01.2014 |
14.02.2014 |
14.02.2014 |
Неактивен |
3864 |
| Perindopril, Indapamide |
20110360 |
Pontea, Film coated tablet, 4 mg/ 1,25 mg, mg, Pack: 30 |
Stada Arzneimittel AG, Германия |
Glenmark Pharmaceutical Ltd – UK; Glenmark Pharmaceutical sro – Czech Rep |
7.78 |
1.56 |
9.34 |
7% |
0.54 |
8.32 |
1.66 |
9.98 |
20% |
1.56 |
9.88 |
1.98 |
11.86 |
|
КЦРР-1358/05.09.2012 |
02.10.2012 |
02.10.2012 |
Неактивен |
3864 |
| Perindopril, Indapamide |
20110359 |
Pontea, Film coated tablet, 2 mg/ 0,625 mg, mg, Pack: 30 |
Stada Arzneimittel AG, Германия |
Glenmark Pharmaceutical Ltd – UK; Glenmark Pharmaceutical sro – Czech Rep. |
4.79 |
0.96 |
5.75 |
7% |
0.34 |
5.13 |
1.03 |
6.16 |
20% |
0.96 |
6.09 |
1.22 |
7.31 |
|
КЦРР-1227/13.08.2012 |
14.09.2012 |
14.09.2012 |
Неактивен |
2479 |
| Topotecan |
EU/1/10/660/002 |
POTACTASOL, Powder for concentrate for solution for infusion, 4, mg, Pack: 1 |
Actavis Group PTC ehf., Исландия |
S.C. Sindann-Pharma S.R.L., Romania |
59.4 |
11.88 |
71.28 |
4% |
2.38 |
61.78 |
12.36 |
74.14 |
16% |
9.5 |
71.28 |
14.26 |
85.54 |
|
НСР-3817/16.06.2014 |
01.07.2014 |
01.07.2014 |
Активен |
2969 |
| Topotecan |
EU/1/10/660/002 |
POTACTASOL, Powder for concentrate for solution for infusion, 4, mg, Pack: 1 |
Actavis Group PTC ehf., Исландия |
S.C. Sindann-Pharma S.R.L., Romania |
153.61 |
30.72 |
184.33 |
4% |
6.14 |
159.75 |
31.95 |
191.7 |
16% |
24.58 |
184.33 |
36.87 |
221.2 |
|
КЦРР-2961/20.03.2013 |
24.04.2013 |
24.04.2013 |
Неактивен |
2969 |
| Topotecan |
EU/1/10/660/002 |
POTACTASOL, Powder for concentrate for solution for infusion, 4, mg, Pack: 1 |
Actavis Group PTC ehf., Исландия |
S.C. Sindann-Pharma S.R.L., Romania |
284.24 |
56.85 |
341.09 |
4% |
10 |
294.24 |
58.85 |
353.09 |
16% |
25 |
319.24 |
63.85 |
383.09 |
|
КЦ-2433/06.07.2011 |
26.07.2011 |
26.07.2011 |
Неактивен |
2969 |
| Tuberculini purified Protein Derivative for human use |
20000719 |
PPD Tuberculin Mammalian, Solution for injection, 5 TU/0.1 ml - 1 ml, -, Pack: x 10 флакони (10 дози) |
БУЛ БИО-НЦЗПБ ЕООД, България |
БУЛ БИО -НЦЗПБ ЕООД, София, България |
66 |
13.2 |
79.2 |
4% |
2.64 |
68.64 |
13.73 |
82.37 |
16% |
10.56 |
79.2 |
15.84 |
95.04 |
|
НСР-9381/01.06.2016 |
02.07.2016 |
02.07.2016 |
Активен |
15138 |
| Tuberculini purified Protein Derivative for human use |
0995/05.11.2007 г. |
PPD Tuberculin Mammalian, Solution for injection, 5 TU/0,1 ml, -, Pack: 1 fl. x 1 ml (10 doses) |
БУЛ БИО-НЦЗПБ ЕООД, България |
БУЛ БИО-НЦЗПБ ЕООД |
35 |
7 |
42 |
4% |
1.4 |
36.4 |
7.28 |
43.68 |
16% |
5.6 |
42 |
8.4 |
50.4 |
протокол № 174/19.05.2016 |
КЦ-117/23.06.2008 |
23.07.2008 |
23.07.2008 |
Активен |
66 |
| Tuberculini purified Protein Derivative for human use |
0995/05.11.2007 г. |
PPD Tuberculin Mammalian, Solution for injection, 5 TU/0,1 ml, -, Pack: 10 ampoules |
БУЛ БИО-НЦЗПБ ЕООД, България |
БУЛ БИО-НЦЗПБ ЕООД |
35 |
7 |
42 |
4% |
1.4 |
36.4 |
7.28 |
43.68 |
16% |
5.6 |
42 |
8.4 |
50.4 |
|
КЦ-117/23.06.2008 |
23.07.2008 |
23.07.2008 |
Неактивен |
66 |
| Dabigatran etexilate |
EU/1/08/442/011 |
PRADAXA, Capsule, hard, 150, mg, Pack: 60 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
110.95 |
22.19 |
133.14 |
4% |
4.44 |
115.39 |
23.08 |
138.47 |
16% |
17.75 |
133.14 |
26.63 |
159.77 |
корекционно решение НСР-10552/06.10.2016. |
НСР-7654/01.12.2015.; НСР-10346/26.09.2016. |
02.11.2016 |
02.11.2016 |
Активен |
2546 |
| Dabigatran etexilate |
EU/1/08/442/011 |
PRADAXA, Capsule, hard, 150, mg, Pack: 60 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
111.99 |
22.4 |
134.39 |
4% |
4.48 |
116.47 |
23.29 |
139.76 |
16% |
17.92 |
134.39 |
26.88 |
161.27 |
|
НСР-7654/01.12.2015. |
16.12.2015 |
16.12.2015 |
Неактивен |
2546 |
| Dabigatran etexilate |
EU/1/08/442/011 |
PRADAXA, Capsule, hard, 150, mg, Pack: 60 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
113.83 |
22.77 |
136.6 |
4% |
4.55 |
118.38 |
23.68 |
142.06 |
16% |
18.21 |
136.59 |
27.32 |
163.91 |
|
НСР-2857/21.02.2014 |
10.03.2014 |
10.03.2014 |
Неактивен |
2546 |
| Dabigatran etexilate |
EU/1/08/442/011 |
PRADAXA, Capsule, hard, 150, mg, Pack: 60 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
117.35 |
23.47 |
140.82 |
4% |
4.69 |
122.04 |
24.41 |
146.45 |
16% |
18.78 |
140.82 |
28.16 |
168.98 |
|
HCР-285/28.06.2013. |
16.07.2013 |
16.07.2013 |
Неактивен |
2546 |
| Dabigatran etexilate |
EU/1/08/442/011 |
PRADAXA, Capsule, hard, 150, mg, Pack: 60 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
134.95 |
26.99 |
161.94 |
4% |
5.4 |
140.35 |
28.07 |
168.42 |
16% |
21.59 |
161.94 |
32.39 |
194.33 |
|
КЦ-2710/13.09.2011 |
27.09.2011 |
27.09.2011 |
Неактивен |
2546 |
| Dabigatran etexilate |
EU/1/08/442/006 |
PRADAXA, Capsule, hard, 110, mg, Pack: 30 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
56 |
11.2 |
67.2 |
4% |
2.24 |
58.24 |
11.65 |
69.89 |
16% |
8.96 |
67.2 |
13.44 |
80.64 |
|
НСР-7653/01.12.2015. |
16.12.2015 |
16.12.2015 |
Активен |
2545 |
| Dabigatran etexilate |
EU/1/08/442/002 |
PRADAXA, Capsule, hard, 75, mg, Pack: 30 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
56 |
11.2 |
67.2 |
4% |
2.24 |
58.24 |
11.65 |
69.89 |
16% |
8.96 |
67.2 |
13.44 |
80.64 |
|
НСР-7654/01.12.2015. |
16.12.2015 |
16.12.2015 |
Активен |
2543 |
| Dabigatran etexilate |
EU/1/08/442/006 |
PRADAXA, Capsule, hard, 110, mg, Pack: 30 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
56.91 |
11.38 |
68.29 |
4% |
2.28 |
59.19 |
11.84 |
71.03 |
16% |
9.11 |
68.3 |
13.66 |
81.96 |
|
НСР-2857/21.02.2014 |
10.03.2014 |
10.03.2014 |
Неактивен |
2545 |
| Dabigatran etexilate |
EU/1/08/442/002 |
PRADAXA, Capsule, hard, 75, mg, Pack: 30 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
56.91 |
11.38 |
68.29 |
4% |
2.28 |
59.19 |
11.84 |
71.03 |
16% |
9.11 |
68.3 |
13.66 |
81.96 |
корекц. Решение НСР-3024/12.03.2014; корекц. Решение НСР-7542/19.11.2015 |
НСР-2857/21.02.2014 |
10.03.2014 |
10.03.2014 |
Неактивен |
2543 |
| Dabigatran etexilate |
EU/1/08/442/006 |
PRADAXA, Capsule, hard, 110, mg, Pack: 30 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
58.67 |
11.73 |
70.4 |
4% |
2.35 |
61.02 |
12.2 |
73.22 |
16% |
9.39 |
70.41 |
14.08 |
84.49 |
|
HCР-286/28.06.2013. |
16.07.2013 |
16.07.2013 |
Неактивен |
2545 |
| Dabigatran etexilate |
EU/1/08/442/001 |
PRADAXA, Capsule, hard, 75, mg, Pack: 30 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
58.67 |
11.73 |
70.4 |
4% |
2.35 |
61.02 |
12.2 |
73.22 |
16% |
9.39 |
70.41 |
14.08 |
84.49 |
|
HCР-288/28.06.2013. |
16.07.2013 |
16.07.2013 |
Неактивен |
2543 |
| Dabigatran etexilate |
EU/1/08/442/006 |
PRADAXA, Capsule, hard, 110, mg, Pack: 30 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
98.69 |
19.74 |
118.43 |
4% |
3.95 |
102.64 |
20.53 |
123.17 |
16% |
15.79 |
118.43 |
23.69 |
142.12 |
|
КЦ-2712/13.09.2011 |
27.09.2011 |
27.09.2011 |
Неактивен |
2545 |
| Dabigatran etexilate |
EU/1/08/442/002 |
PRADAXA, Capsule, hard, 75, mg, Pack: 30 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
98.69 |
19.74 |
118.43 |
4% |
3.95 |
102.64 |
20.53 |
123.17 |
16% |
15.79 |
118.43 |
23.69 |
142.12 |
|
КЦ-2719/13.09.2011 |
27.09.2011 |
27.09.2011 |
Неактивен |
2543 |